Work

Newly Diagnosed Bullous Pemphigoid in a Patient Receiving Sitagliptin

Year: 2024

Type: article

Abstract: Bullous pemphigoid (BP) is the most common autoimmune skin blistering disorder in the general population. The disease often presents in the seventh and eighth decades of life. Several identified triggers contribute to the pathogenesis of BP. One of these triggers includes the dipeptidyl peptidase-4 (DPP-4) inhibitors, linagliptin and vildagliptin. These medications are used primarily as therapy for type 2 diabetes mellitus. Current literature does not suggest that BP is a class effect of DPP-4 inhibitors. We present a case of an 81-year-old man who developed BP in the setting of another DPP-4 inhibitor, sitagliptin.

Source: Annals of Internal Medicine Clinical Cases

DOI: 10.7326/aimcc.2024.0508

Authors: Jonah Benjamin Haber, Harish Srinivasan, Nicolette Corrao, Mridula Sree Naagendran, Madura Saravanan

Institutions: University of Connecticut, UConn Health, The Hospital of Central Connecticut

Language: English

Topic: Autoimmune Bullous Skin Diseases

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4404066533

FWCI:

Cites: 13

Cited by:

Related to: 10